Health tech firm raises funds for AI development
Ahealth tech business has raised £6.25m in a share placing that will fuel further expansion.
Intelligent Ultrasound Group, which was previously called Medaphor, raised the money through the conditional issue of 62.5 million shares.
The Cardiff-based company is also proposing to raise a further £250,000 through the issue of 2.5 million shares.
Stuart Gall, chief executive of Cardiff-based and Alternative Investement Market-listed Intelligent Ultrasound, said: “This is an exciting time for the group.
“The fundraise will enable us to bring our first Intelligent Ultrasound products to market under the group’s recently signed OEM agreement, complete the development and launch our second AI product, as well as accelerating the development of a range of follow-on clinical AI products.
“We believe the market for AIbased software tools, in the realtime
ultrasound image analysis sector, has considerable potential and we would like to thank both our new and existing shareholders for their support.”
The new investment will be used to complete the development and launch of the first ScanNav products to market under Intelligent Ultrasound’s recently announced OEM agreement.
It will also complete the development of the company’s second ScanNav product and launch to market under a second OEM agreement.
ScanNav uses artificial intelligence to carry out a real-time automated review of ultrasound images while the patient is being scanned.
It opens up the possibility for pregnant women to have their scans at their local GP surgery or health centre, with the results interpreted by their GP or a nurse.
Medaphor, which was a spinout from Cardiff University, changed its name at the start of the year to Intelligent Ultrasound Group.
Intelligent Ultrasound recently entered into a collaboration with the National Imaging Academy Wales (NIAW) to develop artificial intelligence (AI) tools to aid ultrasound scanning and to enhance ultrasound education.
The share placing is conditional on shareholder approval at the company’s next general meeting at the end of the month.
We believe the market for AI-based tools in the real-time ultrasound image analysis sector has considerable potential STUART GALL